Xenon Pharmaceuticals XENE Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Axsome TherapeuticsAXSM

$646K+91.7%

Stoke Therapeutics, Inc.STOK

$2.43M+3.5%

Praxis Precision Medicines, Inc.PRAX

$1.09M+44.0%

BiohavenBHVN

$5.9M+25.3%

Alto NeuroscienceANRO

$1.3M+48.9%

Rapport Therapeutics, Inc.RAPP

$2.47M+40.6%

FAQ

What is Xenon Pharmaceuticals's operating lease liabilities (current)?

Xenon Pharmaceuticals (XENE) reported operating lease liabilities (current) of $1.34M in Q2 2026.

How has Xenon Pharmaceuticals's operating lease liabilities (current) changed year-over-year?

Xenon Pharmaceuticals's operating lease liabilities (current) decreased by 8.3% year-over-year, from $1.46M to $1.34M.

What is the long-term trend for Xenon Pharmaceuticals's operating lease liabilities (current)?

Over 5 years (2020 to 2025), Xenon Pharmaceuticals's operating lease liabilities (current) has grown at a 42.0% compound annual growth rate (CAGR), from $265K to $1.53M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.